Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;102(1):207-208.
doi: 10.1016/j.kint.2022.05.004. Epub 2022 May 14.

Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses

Moritz Anft  1 , Arturo Blazquez-Navarro  2 , Michael Frahnert  3 , Lutz Fricke  3 , Toni L Meister  4 , Toralf Roch  2 , Ulrik Stervbo  1 , Stephanie Pfaender  4 , Timm H Westhoff  1 , Nina Babel  5
Affiliations

Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses

Moritz Anft et al. Kidney Int. 2022 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of humoral and cellular immunity directed against spike protein (S-protein) derived from Omicron, Delta, and wild-type (WT) variants of concern in hemodialysis patients vaccinated with 4 mRNA coronavirus disease 2019 (COVID-19) vaccine doses. (a) Isolated serum from hemodialysis patients was analyzed for Omicron-, Delta-, and WT-specific neutralizing antibodies (50% Neutralizing Dose [ND50]). (b–f) Isolated peripheral blood mononuclear cells from hemodialysis patients were stimulated for 16 hours with 1 μg/ml severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S-protein overlapping peptide pools from WT (dark red box plots), Delta (light red box plots), or Omicron (blue box plots). S-protein–reactive T helper cells were identified as life/dead-marker–CD3+CD4+CD137+CD154+ (b), and S-protein–reactive cytotoxic T cells were identified as life/dead-marker–CD3+CD8+CD137+ (c). Within the S-protein–reactive CD4 T-cell population, antibodies against interferon-γ (IFN-γ) (d), interleukin-2 (IL-2) (e), and tumor necrosis factor (TNF) (f) were used to detect T helper cell 1 cytokine-producing T helper cells. Groups were compared using 2-sided, unpaired Mann-Whitney U test; P ≤ 0.050 was defined as significant.
See this image and copyright information in PMC

References

    1. GeurtsvanKessel C.H., Geers D., Schmitz K.S., et al. Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol. 2022;7:1–15. - PMC - PubMed
    1. Ariën K.K., Heydrickx L., Michiels J., et al. Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. NPJ Vaccines. 2022;7:4–6. - PMC - PubMed
    1. Hoffmann M., Krüger N., Schulz S., et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185:447–456. - PMC - PubMed
    1. Arora P., Zhang L., Rocha C., et al. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. Lancet Infect Dis. 2022;22:766–767. - PMC - PubMed
    1. Cinkilic O., Anft M., Blazquez-Navarro A., et al. Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses. Kidney Int. 2022;101:1287–1289. - PMC - PubMed

Publication types

Supplementary concepts